{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:19:53Z","timestamp":1792703993649,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.rmed.2023.107285","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T14:09:49Z","timestamp":1686146989000},"page":"107285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: Findings from CHRONICLE"],"prefix":"10.1016","volume":"216","author":[{"suffix":"Jr.","given":"Reynold A.","family":"Panettieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-7105","authenticated-orcid":false,"given":"Njira","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley E.","family":"Chipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Jepson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0872-8023","authenticated-orcid":false,"given":"Wenjiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3782-4743","authenticated-orcid":false,"given":"Eduardo","family":"Genofre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna D.","family":"Carstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.rmed.2023.107285_bib1","first-page":"S2","article-title":"Asthma: definitions and pathophysiology","volume":"5","author":"Mims","year":"2015","journal-title":"Int. Forum Allergy Rhinol."},{"issue":"4","key":"10.1016\/j.rmed.2023.107285_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.rmed.2023.107285_bib3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1164\/rccm.201809-1817PP","article-title":"Unmet needs in severe asthma subtyping and precision medicine trials. Bridging clinical and patient perspectives","volume":"199","author":"Siddiqui","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2023.107285_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/POR.S251120","article-title":"The CHRONICLE study of US adults with subspecialist-treated severe asthma: objectives, design, and initial results","volume":"11","author":"Ambrose","year":"2020","journal-title":"Pragmatic Observational Res."},{"issue":"1","key":"10.1016\/j.rmed.2023.107285_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00024-2015","article-title":"Management of the patient with eosinophilic asthma: a new era begins","volume":"1","author":"de Groot","year":"2015","journal-title":"ERJ Open Res."},{"issue":"10056","key":"10.1016\/j.rmed.2023.107285_bib6","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rmed.2023.107285_bib7","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2023.107285_bib8","series-title":"FASENRA (Benralizumab) Injection, for Subcutaneous Use","year":"2021"},{"issue":"3","key":"10.1016\/j.rmed.2023.107285_bib9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"10056","key":"10.1016\/j.rmed.2023.107285_bib10","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.rmed.2023.107285_bib11","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.rmed.2023.107285_bib12","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Bourdin","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2023.107285_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/JAA.S227170","article-title":"Two-year integrated efficacy and safety analysis of benralizumab in severe asthma","volume":"12","author":"FitzGerald","year":"2019","journal-title":"J. Asthma Allergy"},{"issue":"2, Supplement","key":"10.1016\/j.rmed.2023.107285_bib14","first-page":"AB249","article-title":"Elimination of oral corticosteroids (OCS) with benralizumab treatment in OCS-dependent asthmatics using a rapid, personalized algorithm: the PONENTE trial","volume":"147","author":"Menzies-Gow","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"12","key":"10.1016\/j.rmed.2023.107285_bib15","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"6","key":"10.1016\/j.rmed.2023.107285_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2023.107285_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2023.107285_bib18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaip.2020.09.060","article-title":"Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan","volume":"9","author":"Abe","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"6","key":"10.1016\/j.rmed.2023.107285_bib19","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jaip.2021.02.048","article-title":"Real-world effectiveness of anti-IL-5\/5R therapy in severe atopic eosinophilic asthma with fungal sensitization","volume":"9","author":"Dhariwal","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2023.107285_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2022.02.017","article-title":"Real-world Effectiveness of Benralizumab: Results from the ZEPHYR 1 Study","author":"Chung","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"10","key":"10.1016\/j.rmed.2023.107285_bib21","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1080\/02770903.2019.1633664","article-title":"The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization","volume":"57","author":"Viinanen","year":"2020","journal-title":"J. Asthma"},{"issue":"1","key":"10.1016\/j.rmed.2023.107285_bib22","article-title":"Characterization and burden of severe eosinophilic asthma in New Zealand: results from the HealthStat Database","volume":"15","author":"Shantakumar","year":"2020","journal-title":"Multidiscip. Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2023.107285_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2003.10.041","article-title":"Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation","volume":"113","author":"Miranda","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2023.107285_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","article-title":"Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population","volume":"73","author":"Kerkhof","year":"2018","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.rmed.2023.107285_bib25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12890-020-01220-9","article-title":"Real-life experience with benralizumab during 6 months","volume":"20","author":"Padilla-Galo","year":"2020","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2023.107285_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/JAA.S297273","article-title":"Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression","volume":"14","author":"Pelaia","year":"2021","journal-title":"J. Asthma Allergy"},{"issue":"2","key":"10.1016\/j.rmed.2023.107285_bib27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123001737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123001737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T02:09:43Z","timestamp":1756692583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611123001737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":27,"alternative-id":["S0954611123001737"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107285","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: Findings from CHRONICLE","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107285"}}